Circulating ADAM17 level reflects disease activity in proteinase-3 ANCA-associated vasculitis

Journal of the American Society of Nephrology

Volumn 26, Issue 11, 2015, Pages 2860-2870

  Bertram, Anna ^a   Lovric, Svjetlana ^a   Engel, Alissa ^a   Beese, Michaela ^a   Wyss, Kristin ^a   Hertel, Barbara ^a   Park, Joon Keun ^a   Becker, Jan U ^a   Kegel, Johanna ^a   Haller, Hermann ^a   Haubitz, Marion ^a,b   Kirsch, Torsten ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b KLINIKUM FULDA   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

A DISINTEGRIN AND METALLOPROTEINASE DOMAIN CONTAINING PROTEIN 17; ADAM PROTEIN; ADAM10 ENDOPEPTIDASE; BIOLOGICAL MARKER; INTERLEUKIN 6; MICRORNA; MICRORNA 1224 3P; MICRORNA 1228; MICRORNA 1229; MICRORNA 1234; MICRORNA 1249; MICRORNA 1268; MICRORNA 1275; MICRORNA 1281; MICRORNA 1293; MICRORNA 150; MICRORNA 3125; MICRORNA 3131; MICRORNA 3147; MICRORNA 3153; MICRORNA 363; MICRORNA 3652; MICRORNA 4281; MICRORNA 466; MICRORNA 483 5P; MICRORNA 574 5P; MICRORNA 634; MYELOBLASTIN; SYNDECAN 1; TISSUE INHIBITOR OF METALLOPROTEINASE 3; UNCLASSIFIED DRUG; ADAM17 PROTEIN, HUMAN; CYTOKINE; IL6 PROTEIN, HUMAN; MIRN-634 MICRORNA, HUMAN; TUMOR NECROSIS FACTOR ALPHA CONVERTING ENZYME;

ADULT; ANCA ASSOCIATED VASCULITIS; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; DISEASE ACTIVITY; DISEASE ASSOCIATION; ENDOTHELIAL MICROPARTICLE; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; INFLAMMATION; MACROPHAGE; MALE; MIDDLE AGED; MONOCYTE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN SECRETION; VASCULAR ENDOTHELIUM; AGED; BLOOD; CARDIOVASCULAR DISEASE; CELL CULTURE; CYTOLOGY; FLOW CYTOMETRY; GENE EXPRESSION REGULATION; IMMUNOASSAY; IMMUNOLOGY; METABOLISM; PHYSIOLOGY;

ADAM PROTEINS; ADAM17 PROTEIN; ADULT; AGED; ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS; CARDIOVASCULAR DISEASES; CELLS, CULTURED; CYTOKINES; ENDOTHELIUM, VASCULAR; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION REGULATION; HUMANS; IMMUNOASSAY; INFLAMMATION; INTERLEUKIN-6; MACROPHAGES; MALE; MICRORNAS; MIDDLE AGED; MYELOBLASTIN; PHENOTYPE;

EID: 84946085148     PISSN: 10466673     EISSN: 15333450     Source Type: Journal    
DOI: 10.1681/ASN.2014050477     Document Type: Article

References (50)

1. Jennette JC, Falk RJ: Small-vessel vasculitis. N Engl J Med 337: 1512 1523, 1997
2. Jennette JC, Falk RJ, Andrassy K, Bacon PA, Churg J, GrossWL, Hagen EC, Hoffman GS, Hunder GG, Kallenberg CG,Mccluskey RT, Sinico RA, Rees AJ, Van Es LA,Waldherr R,Wiik A, Seruminstitut S: Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum 37: 187-192, 1994
3. Falk RJ, Jennette JC: Anti-neutrophil cytoplasmic autoantibodies with specificity for myeloperoxidase in patients with systemic vasculitis and idiopathic necrotizing and crescentic glomerulonephritis.NEngl JMed 318: 1651-1657, 1988
4. Jennette JC, Hoidal JR, Falk RJ: Specificity of anti-neutrophil cytoplasmic autoantibodies for proteinase 3. Blood 75: 2263-2264, 1990
5. Kain R, Exner M, Brandes R, Ziebermayr R, Cunningham D, Alderson CA, Davidovits A, Raab I, Jahn R, Ashour O, Spitzauer S, Sunder Plassmann G, Fukuda M, Klemm P, Rees AJ, Kerjaschki D: Molecular mimicry in pauci-immune focal necrotizing glomerulonephritis. Nat Med 14: 1088-1096, 2008
6. Roth AJ, Brown MC, Smith RN, Badhwar AK, Parente O, Chung H, Bunch DO, McGregor JG, Hogan SL, Hu Y, Yang JJ, Berg EA, Niles J, Jennette JC, Preston GA, Falk RJ: Anti-LAMP-2 antibodies are not prevalent in patients with antineutrophil cytoplasmic autoantibody glomerulonephritis. J AmSoc Nephrol 23: 545-555, 2012
7. Fujimoto S, Watts RA, Kobayashi S, Suzuki K, Jayne DR, Scott DG, Hashimoto H, Nunoi H: Comparison of the epidemiology of anti-neutrophil cytoplasmic antibody-associated vasculitis between Japan and the U.K. Rheumatology (Oxford) 50: 1916-1920, 2011
8. Nowack R, Schwalbe K, Flores-Suárez LF, Yard B, van der Woude FJ: Upregulation of CD14 and CD18 on monocytes in vitro by antineutrophil cytoplasmic autoantibodies. J Am Soc Nephrol 11: 1639 1646, 2000
9. van Rossum AP, Rarok AA, Huitema MG, Fassina G, Limburg PC, Kallenberg CG: Constitutive membrane expression of proteinase 3 (PR3) and neutrophil activation by anti-PR3 antibodies. J Leukoc Biol 76: 1162-1170, 2004
10. Tomasson G, Lavalley M, Tanriverdi K, Finkielman JD, Davis JC Jr, Hoffman GS, McCune WJ, St Clair EW, Specks U, Spiera R, Stone JH, Freedman JE, Merkel PA; Wegener's Granulomatosis Etanercept Trial (WGET) Research Group: Relationship between markers of platelet activation and inflammation with disease activity in Wegener's granulomatosis. J Rheumatol 38: 1048-1054, 2011
11. Schneeweis C, Rafalowicz M, Feist E, Buttgereit F, Rudolph PE, Burmester GR, Egerer K: Increased levels of BLyS and sVCAM-1 in antineutrophil cytoplasmatic antibody (ANCA)-associated vasculitides (AAV). Clin Exp Rheumatol 28[Suppl 57]: 62-66, 2010
12. Nogueira E, Hamour S, Sawant D, Henderson S, Mansfield N, Chavele KM, Pusey CD, Salama AD: Serum IL-17 and IL-23 levels and autoantigenspecific Th17 cells are elevated in patients with ANCA-associated vasculitis. Nephrol Dial Transplant 25: 2209-2217, 2010
13. Noronha IL, Krüger C, Andrassy K, Ritz E,Waldherr R: In situ production of TNF-alpha, IL-1 beta and IL-2R in ANCA-positive glomerulonephritis. Kidney Int 43: 682-692, 1993
14. Ohlsson S, Wieslander J, Segelmark M: Circulating cytokine profile in anti-neutrophilic cytoplasmatic autoantibody-associated vasculitis: Prediction of outcome? Mediators Inflamm 13: 275-283, 2004
15. Woywodt A, Streiber F, de Groot K, Regelsberger H, Haller H, Haubitz M: Circulating endothelial cells as markers for ANCA-associated smallvessel vasculitis. Lancet 361: 206-210, 2003
16. Di Lorenzo G, Pacor ML, Mansueto P, Lo Bianco C, Di Natale E, Rapisarda F, Pellitteri ME, Ditta V, Gioa A, Giammarresi G, Rini GB, Li Vecchi M: Circulating levels of soluble adhesion molecules in patients with ANCA-associated vasculitis. J Nephrol 17: 800-807, 2004
17. Ara J, Mirapeix E, Arrizabalaga P, Rodriguez R, Ascaso C, Abellana R, Font J, Darnell A: Circulating soluble adhesion molecules in ANCAassociated vasculitis. Nephrol Dial Transplant 16: 276-285, 2001
18. Jónasdóttir O, Petersen J, Bendtzen K: Tumour necrosis factor-alpha (TNF), lymphotoxin and TNF receptor levels in serum frompatients with Wegener's granulomatosis. APMIS 109: 781-786, 2001
19. Tesar V,Masek Z, Rychlík I,Merta M, Bartunková J, Stejskalová A, Zabka J, Janatková I, Fuciková T, Dostál C, Becvár R: Cytokines and adhesion molecules in renal vasculitis and lupus nephritis. Nephrol Dial Transplant 13: 1662-1667, 1998
20. Schmitt WH, Heesen C, Csernok E, Rautmann A, Gross WL: Elevated serum levels of soluble interleukin-2 receptor in patients with Wegener's granulomatosis. Association with disease activity. Arthritis Rheum 35: 1088-1096, 1992
21. Sanders JS, Huitma MG, Kallenberg CG, Stegeman CA: Plasma levels of soluble interleukin 2 receptor, solubleCD30, interleukin 10 and B cell activator of the tumour necrosis factor family during follow-up in vasculitis associated with proteinase 3-antineutrophil cytoplasmic antibodies: Associations with disease activity and relapse. Ann Rheum Dis 65: 1484-1489, 2006
22. Schönermarck U, Csernok E, Trabandt A, Hansen H, Gross WL: Circulating cytokines and soluble CD23, CD26 and CD30 in ANCA-associated vasculitides. Clin Exp Rheumatol 18: 457-463, 2000
23. Black RA, Rauch CT, Kozlosky CJ, Peschon JJ, Slack JL, Wolfson MF, Castner BJ, Stocking KL, Reddy P, Srinivasan S, Nelson N, Boiani N, Schooley KA, Gerhart M, Davis R, Fitzner JN, Johnson RS, Paxton RJ, March CJ, Cerretti DP: A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells. Nature 385: 729-733, 1997
24. Moss ML, Jin SL, Milla ME, Burkhart W, Carter HL, Chen WJ, Clay WC, Didsbury JR, Hassler D, Hoffman CR, Kost TA, Lambert MH, Leesnitzer MA, McCauley P, McGeehan G, Mitchell J, Moyer M, Pahel G, Rocque W, Overton LK, Schoenen F, Seaton T, Su JL, Warner J, Williard D, Becherer JD: Cloning of a disintegrin metalloproteinase that processes precursor tumour-necrosis factor-a. Nature 385: 733-736, 1997
25. Dreymueller D, Pruessmeyer J, Groth E, Ludwig A: The role of ADAMmediated shedding in vascular biology. Eur J Cell Biol 91: 472-485, 2012
26. Peschon JJ, Slack JL, Reddy P, Stocking KL, Sunnarborg SW, Lee DC, Russell WE, Castner BJ, Johnson RS, Fitzner JN, Boyce RW, Nelson N, Kozlosky CJ,WolfsonMF, Rauch CT, Cerretti DP, Paxton RJ, March CJ, Black RA: An essential role for ectodomain shedding in mammalian development. Science 282: 1281-1284, 1998
27. LeRouxS, PepperRJ,DufayA,NéelM,Meffray E, LamandéN,Rimbert M, Josien R, Hamidou M, Hourmant M, Cook HT, Charreau B, Larger E, Salama AD, Fakhouri F: Elevated soluble Flt1 inhibits endothelial repair in PR3-ANCA-associated vasculitis. J Am Soc Nephrol 23: 155-164, 2012
28. Rahimi N, Golde TE, Meyer RD: Identification of ligand-induced proteolytic cleavage and ectodomain shedding of VEGFR-1/FLT1 in leukemic cancer cells. Cancer Res 69: 2607-2614, 2009
29. Garton KJ, Gough PJ, Philalay J, Wille PT, Blobel CP, Whitehead RH, Dempsey PJ, Raines EW: Stimulated shedding of vascular cell adhesion molecule 1 (VCAM-1) is mediated by tumor necrosis factor-alphaconverting enzyme (ADAM 17). J Biol Chem278: 37459-37464, 2003
30. Tsakadze NL, Sithu SD, Sen U, English WR, Murphy G, D'Souza SE: Tumor necrosis factor-alpha-converting enzyme (TACE/ADAM-17) mediates the ectodomain cleavage of intercellular adhesion molecule 1 (ICAM-1). J Biol Chem281: 3157-3164, 2006
31. Saftig P, Reiss K: The "A Disintegrin And Metalloproteases" ADAM10 and ADAM17: Novel drug targets with therapeutic potential? Eur J Cell Biol 90: 527-535, 2011
32. Scheller J, Chalaris A, Garbers C, Rose-John S: ADAM17: A molecular switch to control inflammation and tissue regeneration. Trends Immunol 32: 380-387, 2011
33. Lisi S, D'Amore M, Sisto M: ADAM17 at the interface between inflammation and autoimmunity. Immunol Lett 162: 159-169, 2014
34. Bishop JR, Schuksz M, Esko JD: Heparan sulphate proteoglycans finetune mammalian physiology. Nature 446: 1030-1037, 2007
35. Tkachenko E, Rhodes JM, Simons M: Syndecans: New kids on the signaling block. Circ Res 96: 488-500, 2005
36. Voyvodic PL, Min D, Liu R, Williams E, Chitalia V, Dunn AK, Baker AB: Loss of syndecan-1 induces a pro-inflammatory phenotype in endothelial cells with a dysregulated response to atheroprotective flow. J Biol Chem289: 9547-9559, 2014
37. Lorenzen I, Lokau J, Düsterhöft S, Trad A, Garbers C, Scheller J, Rose John S, Grötzinger J: Themembrane-proximal domain of A Disintegrin andMetalloprotease 17 (ADAM17) is responsible for recognition of the interleukin-6 receptor and interleukin-1 receptor II. FEBS Lett 586: 1093-1100, 2012
38. Le Gall SM, Bobé P, Reiss K, Horiuchi K, Niu XD, Lundell D, Gibb DR, Conrad D, Saftig P, Blobel CP: ADAMs 10 and 17 represent differentially regulated components of a general shedding machinery for membrane proteins such as transforming growth factor alpha, L-selectin, and tumor necrosis factor alpha.Mol Biol Cell 20: 1785-1794, 2009
39. Biró E, Akkerman JW, Hoek FJ, GorterG, Pronk LM, Sturk A, Nieuwland R: The phospholipid composition and cholesterol content of plateletderived microparticles: A comparison with platelet membrane fractions. J Thromb Haemost 3: 2754-2763, 2005
40. Tellier E, Canault M, Rebsomen L, Bonardo B, Juhan-Vague I, Nalbone G, Peiretti F: The shedding activity of ADAM17 is sequestered in lipid rafts. Exp Cell Res 312: 3969-3980, 2006
41. Del Conde I, Shrimpton CN, Thiagarajan P, López JA: Tissue-factorbearing microvesicles arise from lipid rafts and fuse with activated platelets to initiate coagulation. Blood 106: 1604-1611, 2005
42. Lee JH, Wittki S, Bräu T, Dreyer FS, Krätzel K, Dindorf J, Johnston IC, Gross S, Kremmer E, Zeidler R, Schlötzer-Schrehardt U, Lichtenheld M, Saksela K, Harrer T, Schuler G, Federico M, Baur AS: HIV Nef, paxillin, and Pak1/2 regulate activation and secretion of TACE/ADAM10 proteases. Mol Cell 49: 668-679, 2013
43. Erdbruegger U, Grossheim M, Hertel B, Wyss K, Kirsch T, Woywodt A, Haller H, Haubitz M: Diagnostic role of endothelial microparticles in vasculitis. Rheumatology (Oxford) 47: 1820-1825, 2008
44. Canault M, Leroyer AS, Peiretti F, Lesche G, Tedgui A, Bonardo B, Alessi MC, Boulanger CM, Nalbone G: Microparticles of human atherosclerotic plaques enhance the shedding of the tumor necrosis factoralpha converting enzyme/ADAM17 substrates, tumor necrosis factor and tumor necrosis factor receptor-1. Am J Pathol 171: 1713-1723, 2007
45. Kambas K, Chrysanthopoulou A, Vassilopoulos D, Apostolidou E, Skendros P, Girod A, Arelaki S, Froudarakis M, Nakopoulou L, Giatromanolaki A, Sidiropoulos P, Koffa M, Boumpas DT, Ritis K, Mitroulis I: Tissue factor expression in neutrophil extracellular traps and neutrophil derived microparticles in antineutrophil cytoplasmic antibody associated vasculitis may promotethromboinflammation andthe thrombophilic state associatedwith the disease. Ann Rheum Dis 73: 1854-1863, 2014
46. Hong Y, Eleftheriou D, Hussain AA, Price-Kuehne FE, Savage CO, Jayne D, Little MA, Salama AD, Klein NJ, Brogan PA: Anti-neutrophil cytoplasmic antibodies stimulate release of neutrophil microparticles. J Am Soc Nephrol 23: 49-62, 2012
47. Doberstein K, Steinmeyer N, Hartmetz AK, Eberhardt W, Mittelbronn M, Harter PN, Juengel E, Blaheta R, Pfeilschifter J, Gutwein P: Micro RNA-145 targets the metalloprotease ADAM17 and is suppressed in renal cell carcinoma patients. Neoplasia 15: 218-230, 2013
48. MelenhorstWB, Visser L, Timmer A, van den HeuvelMC, StegemanCA, van Goor H: ADAM17 upregulation in human renal disease: a role in modulating TGF-alpha availability? Am J Physiol Renal Physiol 297: F781-F790, 2009
49. Dey-Hazra E, Hertel B, Kirsch T, Woywodt A, Lovric S, Haller H, Haubitz M, Erdbruegger U: Detection of circulating microparticles by flow cytometry: Influence of centrifugation, filtration of buffer, and freezing. Vasc Health Risk Manag 6: 1125-1133, 2010
50. Beese M, Wyss K, Haubitz M, Kirsch T: Effect of cAMP derivates on assembly and maintenance of tight junctions in human umbilical vein endothelial cells. BMC Cell Biol 11: 68, 2010